Moberg Pharma AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mobergderma.se
Clinical Trials
15
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
- Conditions
- Erythema
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 45
- Registration Number
- NCT06369675
- Locations
- 🇺🇸
TKL Research, Inc, Fair Lawn, New Jersey, United States
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
- Conditions
- Erythema
- Interventions
- Drug: MOB015BDrug: MOB015B vehicleDrug: Negative irritant solution of 0.9% saline
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 250
- Registration Number
- NCT06369727
- Locations
- 🇺🇸
TKL Research, Inc, Fair Lawn, New Jersey, United States
A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
- Conditions
- Onychomycosis
- Interventions
- Drug: MOB015BDrug: Vehicle (Placebo Comparator)
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 350
- Registration Number
- NCT05279846
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Center for Dermatology Clinical Research,Inc, Fremont, California, United States
A Study of the Systemic Absorption of MOB015B
- Conditions
- Onychomycosis
- Interventions
- Drug: MOB015B
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 20
- Registration Number
- NCT03244280
- Locations
- 🇺🇸
Dermatology clinic, Austin, Texas, United States
Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)
- Conditions
- Distal Subungual Onychomycosis
- Interventions
- Drug: MOB015B
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Moberg Pharma AB
- Target Recruit Count
- 452
- Registration Number
- NCT02866032
- Prev
- 1
- 2
- 3
- Next
News
Moberg Pharma's MOB-015 Phase 3 Trial Shows Lower Than Expected Clinical Cure Rate
Moberg Pharma reports that a subset of patients in their North American Phase 3 study of MOB-015 achieved clinical cure for nail fungus at a rate lower than anticipated.